Balversa works by targeting genetic mutations called FGFR3 and FGFR2. FGFR stands for fibroblast growth factor receptors. These are proteins that give cells their orders to grow and divide.

Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect ...

It is estimated that around 15%-20% of bladder cancer patients have some form of FGFR mutation. According to the FDA, FGFRs regulate biological processes including cell growth and division during ...

The research delves into how mutations in FGFR2 and FGFR3 affect mandibular bone formation and endochondral bone repair following non-stabilized fractures. The findings reveal that FGFR ...

which maintains efficacy against resistance mutations, shows potency in gastric cancer animal model, and demonstrates a more favorable safety profile compared to existing FGFR inhibitors.

However, epithelial cancers — such as bladder cancer — also exhibit deregulation and mutation of FGFR3 ... R3Mab reduced the phosphorylation of FGFR substrate 2α and mitogen-activated ...

BALVERSA (erdafitinib) has strong market potential in the FGFR-altered urothelial carcinoma space, particularly as a targeted therapy for patients with FGFR2/3 mutations. With the growing emphasis on ...

which maintains efficacy against resistance mutations, shows potency in gastric cancer animal model, and demonstrates a more favorable safety profile compared to existing FGFR inhibitors.

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...

Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect ...